Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa, Proof-of-Concept Clinical Study to Evaluate AS1411 in COVID-19 Patients

Next Previous
X
Search
Trial Profile

A Phase I/IIa, Proof-of-Concept Clinical Study to Evaluate AS1411 in COVID-19 Patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QN 165 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Qualigen Therapeutics

    • Most Recent Events

    • 14 Jul 2021 According to a Qualigen media release, the company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen's QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients.
    • 05 Nov 2020 According to a Qualigen media release, the company plans to file an IND application with the U.S. Food and Drug Administration in early calendar 2021.
    • 28 Oct 2020 According to a Qualigen Therapeutics media release, it announced receipt of written feedback to its Type B Pre-IND (Pre-Investigational New Drug application) meeting request from the U.S. Food and Drug Administration (FDA) that is in general agreement with the Companys planned clinical development of AS1411, a nucleolin-targeting DNA aptamer drug candidate, for the treatment of COVID-19

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top